Latest Breaking News On - Amgen sponsored phase - Page 1 : vimarsana.com

IDEAYA Biosciences, Inc Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored studyTargeting.

New south walesUnited kingdomWerner helicaseTrodelvy sacituzumab govitecan hziyAnthony joshuaAndres ruiz brisenoYujiros hataDarrin beaupreExchange commissionDarovasertib program in tumorsProgram in solid tumorsEuropean society for medical oncology congressCancer research united kingdomGilead sciencesHead department of medical oncologyKinghorn cancer centre

IDEAYA Biosciences, Inc Reports Second Quarter 2023 Financial Results and Provides Business Update

IDEAYA Biosciences, Inc Reports Second Quarter 2023 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomNew south walesUnited statesYujiros hataWerner helicaseDarrin beaupreBiosciences incUniversity of manchesterPol theta helicase inhibitor developmentAlfred healthProgram updatesExchange commissionCancer research united kingdomEuropean society for medical oncology congressAmgen sponsored phasePol theta helicase

IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors

- First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase.

Darrinm beaupreBiosciences incExchange commissionAmgen sponsored phaseChief medical officerClinical trial collaborationSupply agreementIdeaya biosciences

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors

/PRNewswire/ IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted.

United statesMichael whiteDarrinm beaupreDrug administrationBiosciences incExchange commissionAmgen sponsored phaseAmgen sponsored investigational new drugChief medical officerChief scientific officerClinical trial collaborationSupply agreementAmerican associationCancer researchIdeaya biosciences

IDEAYA Biosciences, Inc Reports 2022 Financial Results and Provides Business Update

Strong balance sheet of ~$373.1 million cash, cash equivalents and marketable securities as of December 31, 2022 is anticipated to fund planned operations into.

New south walesUnited kingdomDarrinm beaupreYujiros hataWerner helicaseMichael whiteUniversity of manchesterExchange commissionBiosciences incCancer research united kingdomAlfred healthProgram updatesPol theta helicaseChief executive officerSenior vice presidentChief medical officer